Sonova Holding AG stock faces revenue pressure after 2025 full-year results miss expectations

Sonova Holding AG stock came under pressure following the release of its fiscal 2025 full-year results on March 23, 2026. The Swiss-based hearing care company posted an 8% drop in sales revenue to 360.2 million from 392.3 million the prior year, reflecting persistent market challenges in key regions. For US investors, this development highlights both risks and opportunities in the global audiology market, where aging populations drive long-term demand despite short-term hurdles.

As of: 24.03.2026

By Elena Voss, Senior Healthcare Equity Analyst: Sonova's latest figures underscore the tension between cyclical pressures and structural growth in hearing health, a sector poised for expansion as demographics shift worldwide.

Full-Year 2025 Results Reveal Revenue Decline

Sonova Holding AG, listed on the SIX Swiss Exchange under ISIN CH0012549785, disclosed its fiscal 2025 financials showing sales revenue of 360.2 million, down 8% from 392.3 million in 2024. This decline stemmed from softer demand in mature markets and inventory adjustments across distribution channels. Despite the top-line setback, the company maintained gross margins, with Bruttomarge I improving to 49.5% from 46.5%.

EBITDA fell 6% to 48.8 million from 51.8 million, while net profit dropped to 16.2 million from 19.2 million. These figures reflect operational efficiencies offsetting some revenue weakness, but investors focused on the underlying sales trend. The balance sheet remained solid, with total assets at 327.8 million versus 331.6 million previously.

Q4 2025 Shows Mixed Recovery Signals

In the fourth quarter, Sonova reported sales of 97.7 million, up from 88.8 million in Q4 2024, marking a positive turn. Profit before taxes surged 75% to 8.1 million, and net profit more than doubled to 6.4 million. Bruttogewinn I rose 8% to 47.5 million with a margin of 48.6%.

This quarterly improvement suggests stabilizing demand, particularly in hearing instruments, Sonova's core segment. However, full-year trends indicate broader challenges like currency headwinds and competitive pricing pressures. Management emphasized progress in cost controls, with operating expenses managed tightly.

Strategic Focus on Hearing Care Innovation

Sonova operates as a holding company with key brands like Phonak and Unitron, dominating the hearing aid market. The 2025 results highlight resilience in product innovation, including over-the-counter (OTC) hearing aids, which gained traction in the US. This segment aligns with FDA approvals for OTC devices, opening doors for broader accessibility.

Company investments in R&D continue to support premium product launches, aiming to capture share in emerging markets. Distribution through independent clinics and retail partners remains a strength, though inventory destocking impacted 2025 sales. Management's outlook points to EBITDA margin expansion in 2026, driven by these initiatives.

US Investor Relevance in Audiology Boom

For US investors, Sonova offers exposure to the $7 billion US hearing aid market, projected to grow at 6% annually through 2030 due to aging Baby Boomers. The stock trades on the SIX Swiss Exchange in CHF, providing diversification from US-listed medtech peers like Sonova's competitors. Recent OTC regulatory shifts favor innovators like Sonova, potentially boosting North American sales.

With 20% of Sonova's revenue from the Americas, US demand dynamics directly influence performance. Investors should monitor how Sonova capitalizes on OTC adoption, where lower-priced devices could expand the addressable market by 10 million potential users. This positions the stock as a play on demographic tailwinds amid global uncertainty.

Outlook and Guidance for Fiscal 2026

Sonova's board anticipates EBITDA margin improvement on a group level for 2026, supported by cost efficiencies and volume recovery. While specific sales guidance was cautious, Q4 momentum suggests stabilization. Key drivers include new product cycles and market share gains in direct-to-consumer channels.

Balance sheet strength, with low net debt, supports buybacks or acquisitions. Dividend policy remains shareholder-friendly, with payouts tied to profitability. Analysts will parse these signals for evidence of a sales inflection, critical for valuation re-rating.

Risks and Open Questions Ahead

Persistent revenue pressure from economic slowdowns in Europe and reimbursement changes pose near-term risks. Competition from big tech entrants in OTC hearing could erode premiums. Currency volatility, given CHF trading, impacts US investors' returns.

Key questions include the durability of Q4 rebound and 2026 margin delivery. Supply chain disruptions in components remain a watch item. Overall, while fundamentals are sound, execution on growth levers will determine stock trajectory.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.